Brentuximab vedotin is currently approved for classical Hodgkin lymphoma (CHL), anaplastic large cell lymphoma (ALCL) (another lymphoma where malignant cells uniformly express CD30), as well as CD30-expressing peripheral T-cell lymphomas and mycosis fungoides (MF) [ADCETRIS prescribing information]. This evidence concerns the gene TNFRSF8 and mycosis fungoides.